GPDA

CAS No. 65096-46-0

GPDA( GPN | Glycylproline p-nitroanilide tosylate )

Catalog No. M24662 CAS No. 65096-46-0

GPDA is a substrate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 28 In Stock
10MG 32 In Stock
25MG 46 In Stock
50MG 55 In Stock
100MG 86 In Stock
200MG 126 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GPDA
  • Note
    Research use only, not for human use.
  • Brief Description
    GPDA is a substrate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay.
  • Description
    GPDA is a substrate of X-Prolyl dipeptidyl-aminopeptidase in the enzyme assay.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GPN | Glycylproline p-nitroanilide tosylate
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    65096-46-0
  • Formula Weight
    464.49
  • Molecular Formula
    C20H24N4O7S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:98 mg/mL (210.98 mM; Need ultrasonic)
  • SMILES
    O=C([C@H](CCC1)N1C(CN)=O)NC2=CC=C([N+]([O-])=O)C=C2.O=S(C3=CC=C(C)C=C3)(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Hino M, et al. X-Prolyl dipeptidyl-aminopeptidase activity, with X-proline p-nitroanilides as substrates, in normal and pathological human sera. Clin Chem. 1976 Aug;22(8):1256-61.
molnova catalog
related products
  • Mogroside III-A2

    Mogroside III-A2 exhibits inhibitory effects with IC50 values of 346-400 mol ratio/32 pmol TPA. and shows weak inhibitory effects on activation of (+/-)-(E)-methyl-2-[(E)-hydroxyimino]-5-nitro-6-methoxy-3-hexemide (NOR 1), a nitric oxide (NO) donor.

  • Lesinurad

    Lesinurad is a selective inhibitor of uric acid reabsorption which is used in combination with other agents in the therapy of gout.

  • AD 01

    FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.